Nothing Special   »   [go: up one dir, main page]

ATE333280T1 - Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen - Google Patents

Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen

Info

Publication number
ATE333280T1
ATE333280T1 AT03703621T AT03703621T ATE333280T1 AT E333280 T1 ATE333280 T1 AT E333280T1 AT 03703621 T AT03703621 T AT 03703621T AT 03703621 T AT03703621 T AT 03703621T AT E333280 T1 ATE333280 T1 AT E333280T1
Authority
AT
Austria
Prior art keywords
treatment
medication
mutation
production
low molecular
Prior art date
Application number
AT03703621T
Other languages
English (en)
Inventor
Vladimir Bykov
Galina Selivanova
Klas Wiman
Original Assignee
Aprea Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200523A external-priority patent/SE0200523D0/xx
Application filed by Aprea Ab filed Critical Aprea Ab
Application granted granted Critical
Publication of ATE333280T1 publication Critical patent/ATE333280T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03703621T 2002-02-21 2003-02-07 Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen ATE333280T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35783102P 2002-02-21 2002-02-21
SE0200523A SE0200523D0 (sv) 2002-02-21 2002-02-21 New compounds

Publications (1)

Publication Number Publication Date
ATE333280T1 true ATE333280T1 (de) 2006-08-15

Family

ID=27759836

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03703621T ATE333280T1 (de) 2002-02-21 2003-02-07 Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen

Country Status (8)

Country Link
US (1) US7659278B2 (de)
EP (1) EP1476166B1 (de)
AT (1) ATE333280T1 (de)
AU (1) AU2003206329B2 (de)
CA (1) CA2476825C (de)
DE (1) DE60306896T2 (de)
ES (1) ES2269975T3 (de)
WO (1) WO2003070250A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1605939T3 (pl) * 2003-03-24 2009-04-30 Aprea Ab Zastosowanie farmaceutyczne 1-azabicyklo[2.2.2]oktanów i sposób testowania zdolności związków do aktywowania nieaktywnego wt p53
SE0400708D0 (sv) 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
US7790474B1 (en) 2005-07-15 2010-09-07 Schering Corporation p53 modulators
ITNA20090047A1 (it) * 2009-07-16 2011-01-17 Adele Bolognese Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
DK2525796T3 (en) 2010-01-21 2016-07-04 Aprea Ab An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
WO2019173806A1 (en) * 2018-03-09 2019-09-12 Texas Tech University System Compositions and methods for the diagnosis and treatment of alt cancer
EP3806850A2 (de) * 2018-06-15 2021-04-21 Ideaya Biosciences, Inc. Verfahren zur hemmung proliferativer zellen
CN112771041A (zh) 2018-09-20 2021-05-07 阿普里治疗公司 奎宁环-3-酮衍生物及其在癌症治疗中的用途
US20220339141A1 (en) 2019-09-18 2022-10-27 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant
WO2022175402A1 (en) 2021-02-18 2022-08-25 Aprea Therapeutics Ab Quinuclidine-3-one derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) * 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6492386B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002024692A1 (en) * 2000-09-20 2002-03-28 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
DE60209471D1 (de) * 2001-03-29 2006-04-27 Topo Target As Copenhagen Koeb Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii

Also Published As

Publication number Publication date
AU2003206329A1 (en) 2003-09-09
EP1476166A1 (de) 2004-11-17
US7659278B2 (en) 2010-02-09
DE60306896D1 (de) 2006-08-31
EP1476166B1 (de) 2006-07-19
DE60306896T2 (de) 2007-02-15
CA2476825C (en) 2011-04-05
AU2003206329B2 (en) 2007-08-09
US20050090510A1 (en) 2005-04-28
ES2269975T3 (es) 2007-04-01
WO2003070250A1 (en) 2003-08-28
CA2476825A1 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
DE60136473D1 (de) Verwendung von 1-azabicyclo(2.2.2)octan-3-on-derivaten zur behandlung von krebstumoren
ATE333280T1 (de) Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
CY1113039T1 (el) Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
DE60010234D1 (de) 2-amino-6-anilino-purine und deren verwendung als arzneimittel
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE60014670D1 (de) Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
ATE402710T1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
ATE383870T1 (de) Behandlung von neurodegenerative krankheiten mit gpr49
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
EA200501711A1 (ru) Семейство секретируемых белков
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
DE60231054D1 (de) Piperidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung zur behandlung von alzheimer-krankheit, die diese derivate enthält
ATE455577T1 (de) Behandlung von neurodegenerativen erkrankungen durch verwendung von laptm4b

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1476166

Country of ref document: EP